The phase 1/2 ILLUMINATE-204 trial studied a combination of TLR-9 agonist tilsotolimod and ipilimumab in patients with metastatic melanoma refractory to anti-PD-1 therapy [76]. Here, TLR9 is linked to metastatic melanoma.